Healthcare 

Canopy Financial
Canopy Financial has raised a $15 million first round from Granite Global Ventures of Menlo Park, Calif. The San Francisco company provides technology and services for large corporations that want to outsource management of their employee's health savings accounts. Before this round, Canopy was funded by angel investors who put roughly $6 million into the company. The money will be used for expansion, product development and staff hirings.

Pharmaceuticals

Zogenix
San Diego pharmaceutical company Zogenix Inc. has raised $18 million in funding. Abingworth Management Ltd. of London led th financing, joined by existing investors Clarus Ventures of Cambridge, Mass., Domain Associates, LLC of Princeton N.J., and Scale Venture Partners of Foster City, Calif. Zogenix will use the proceeds to commercialize sumatriptan DosePro, a migraine treatment for which the company submitted a new drug application with the FDA in December 2007. Zogenix is developing candidates for treatment in neurology and pain.

Media

Outspark
San Francisco online games publisher Outspark landed a key strategic partner and $11 million in fresh capital in a Series B round of venture financing led by Tencent Holdings, China's leader in instant messaging and top Web portal. The deal comes five months after Outspark launched its gaming site, and less than a year from its formation with $4 million in backing from DCM and Altos Ventures, both of Menlo Park, Calif. Outspark founder and CEO Susan Choe said the company was not actively fundraising, but took the investment opportunistically as it enters a strategic relationship with Tencent, which she expects will accelerate the company's move into deeper social networks and online community development. -- Clifford Carlsen

Venture funds

Synergy
Synergy Life Science Partners, LP has closed its debut venture capital investment fund with $143 million in committed capital. The Portola Valley, Calif., fund has already closed on six investments to date. Founded in 2006, Synergy invests in early-stage medical device firms with a focus on cardiovascular disease, orthopedic and spinal diseases and injuries, metabolic disorders such as diabetes and obesity, neuro-mediated disorders, oncology and ophthalmic conditions.